Full-Time
Associate Director
Finance
Posted on 7/19/2025
Stylus Medicine
11-50 employees
In vivo genome editing for CAR-T
No salary listed
Cambridge, MA, USA
In Person
 Accounting (3) |
|---|
| , , |
- Minimum five years of experience in a finance or accounting function.
- Lead the monthly, quarterly and annual accounting close
- Support preparation of monthly, quarterly and annual financial reporting packages
- Manage budgeting and forecasting activities working with team leaders across the company
- Research and prepare technical accounting memos and analyses, as needed
- Champion internal control processes and improvements, including implementing system and process upgrades, as needed
- Oversee operational finance activities, including accounts payable and payroll
- Respond to ad hoc requests for financial support, including supporting tax return preparation
- Attention to detail and strong organizational skills
- Ability to work independently
- Aptitude for process improvement, desire to drive efficiencies and learn the business holistically
- Bachelor’s degree in Finance or Accounting preferred
Stylus Medicine develops in vivo genetic medicines by combining engineered, therapeutic-grade recombinases with non-viral lipid nanoparticle (LNP) delivery. This platform enables sequence-specific genome integration to insert large genetic payloads directly inside a patient’s body, bypassing the complex steps of ex vivo cell modification. The initial focus is in oncology, delivering a recombinase and a CAR-encoding DNA payload to a patient’s T cells via LNP infusion, effectively turning the patient’s body into an in vivo CAR-T cell factory. The modular system can adapt CAR constructs to target different cancer antigens and holds potential for autoimmune and other genetic diseases beyond oncology. The company positions itself as an off-the-shelf, scalable genetic therapy approach that streamlines treatment workflows and broadens patient access by avoiding traditional ex vivo manufacturing.
Company Size
11-50
Company Stage
Series A
Total Funding
$85M
Headquarters
Cambridge, Massachusetts
Founded
2022
Simplify's Take
What believers are saying
- Raised $85M in 2025 from RA Capital, Khosla, Lilly, and J&J.
- Preclinical in vivo CAR-T data presented at ASGCT 2025.
- Led by CEO Nuwaysir with 25+ years in cell therapy.
What critics are saying
- Prime Medicine's PRIME Editing partners with BMS in January 2025.
- Beam's base editing hits 40% efficiency in NHPs at ASGCT May 2025.
- Arc licenses Hsu's IP exclusively to CRISPR Therapeutics February 2026.
What makes Stylus Medicine unique
- Stylus combines engineered recombinases with LNP for in vivo genome integration.
- Platform enables precise insertion of multi-kb payloads into T-cells directly.
- Avoids ex vivo manufacturing complexities of traditional CAR-T therapies.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Professional Development Budget
Company News
Stylus Medicine, a biotech company based in Cambridge, USA, has emerged from stealth mode with $85 million in funding.
Stylus will use the Eli Lilly and J&J-backed funds to advance its in vivo genetic medicines platform and develop its pipeline.
Stylus Medicine has emerged from stealth with $85 million in funding to develop next-gen in vivo genetic medicines. The financing includes a prior $40 million series A and a recent $45 million series A extension, with investors like RA Capital, Khosla Ventures, Eli Lilly, and J&J Innovation. Led by CEO Emile Nuwaysir, Stylus aims to simplify gene editing with a platform featuring recombinase technology. Preclinical data will be presented at the American Society of Gene & Cell Therapy meeting.
Patrick Hsu's startup, Stylus Medicine, has launched with an ambitious goal to develop new gene insertion technologies beyond CRISPR. The company has successfully raised $85 million to support its development efforts.
Stylus Medicine, an ambitious startup founded by Patrick Hsu, has raised $85 million to develop a suite of technologies that it believes...